$1.25
-0.06 (-4.58%)
Open$1.33
Previous Close$1.31
Day High$1.33
Day Low$1.25
52W High$9.48
52W Low$1.30
Volume—
Avg Volume43.5K
Market Cap8.60M
P/E Ratio—
EPS$-1.54
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,365.6% upside
Current
$1.25
$1.25
Target
$30.82
$30.82
$21.30
$30.82 avg
$34.43
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.77M | 10.40M | 9.97M |
| Net Income | -34,356,212 | 1.68M | 1.79M |
| Profit Margin | -1,940.2% | 16.1% | 17.9% |
| EBITDA | -34,210,763 | 3.32M | 3.17M |
| Free Cash Flow | — | 838.7K | 1.16M |
| Rev Growth | — | +2.0% | -1.5% |
| Debt/Equity | — | 0.33 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |